License out our drugs

You are here

Your partner for healthcare innovation


Our business model involves drug discovery and development. After clinical proof-of-concept, Iproteos then licenses the drugs out to third parties to ensure that they reach patients.

At Iproteos, we study and develop new drugs with great social impact, as they will improve the lives of millions of people.

  • Cutting-edge science: we are one of the few biotechnology companies in the world that specialises in peptidomimetic drugs
  • Innovative products in the pipeline
  • Our team comprises people with relevant international experience and a sound track record
  • High returns and social impact

For further information, please contact us.